Corbus Pharmaceuticals Holding (CRBP) - Total Liabilities
Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) has total liabilities worth $24.75 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CRBP asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Corbus Pharmaceuticals Holding - Total Liabilities Trend (2012–2025)
This chart illustrates how Corbus Pharmaceuticals Holding's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Corbus Pharmaceuticals Holding's balance sheet.
Corbus Pharmaceuticals Holding Competitors by Total Liabilities
The table below lists competitors of Corbus Pharmaceuticals Holding ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Information Certificate Authority Inc
KQ:053300
|
Korea | ₩170.54 Billion |
|
Impiana Hotels Bhd
KLSE:7243
|
Malaysia | RM195.30 Million |
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
USA | $44.67 Million |
|
Beijing Tongtech Co Ltd
SHE:300379
|
China | CN¥342.06 Million |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €3.44 Million |
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
USA | $48.06 Million |
|
Acusensus Ltd
AU:ACE
|
Australia | AU$43.22 Million |
|
Hooker Furniture Corporation
NASDAQ:HOFT
|
USA | $54.12 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Corbus Pharmaceuticals Holding's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Corbus Pharmaceuticals Holding net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corbus Pharmaceuticals Holding's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corbus Pharmaceuticals Holding (2012–2025)
The table below shows the annual total liabilities of Corbus Pharmaceuticals Holding from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.69 Million | +53.83% |
| 2024-12-31 | $13.45 Million | -61.76% |
| 2023-12-31 | $35.18 Million | +5.57% |
| 2022-12-31 | $33.32 Million | -13.72% |
| 2021-12-31 | $38.62 Million | -32.27% |
| 2020-12-31 | $57.02 Million | +32.65% |
| 2019-12-31 | $42.98 Million | +120.83% |
| 2018-12-31 | $19.47 Million | +111.70% |
| 2017-12-31 | $9.19 Million | +2.52% |
| 2016-12-31 | $8.97 Million | +130.55% |
| 2015-12-31 | $3.89 Million | +427.11% |
| 2014-12-31 | $738.04K | -64.67% |
| 2013-12-31 | $2.09 Million | +280883.37% |
| 2012-12-31 | $743.36 | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treat… Read more